Participation of elderly adults in randomized controlled trials addressing antibiotic treatment of pneumonia (Q38358209)

2 September 2017

0 references

1 reference

title

Participation of elderly adults in randomized controlled trials addressing antibiotic treatment of pneumonia (English)

1 reference

2 September 2017

0 references

3

Leonard Leibovici

1 reference

2 September 2017

8

Mical Paul

1 reference

2 September 2017

4

Evelina Tacconelli

1 reference

2 September 2017

1

Tomer Avni

1 reference

2 September 2017

Shahaf Shiver-Ofer

2

1 reference

2 September 2017

Giulia DeAngelis

series ordinal

5

1 reference

2 September 2017

Barry Cookson

series ordinal

6

1 reference

2 September 2017

Leonardo Pagani

series ordinal

7

1 reference

2 September 2017

language of work or name

English

0 references

publication date

1 February 2015

1 reference

Journal of the American Geriatrics Society

2 September 2017

1 reference

2 September 2017

63

1 reference

2 September 2017

233-243

1 reference

2 September 2017

2

1 reference

The causes and effects of socio-demographic exclusions from clinical trials

2 September 2017

1 reference

Representation of the elderly, women, and minorities in heart failure clinical trials

21 January 2018

1 reference

Participation of patients 65 years of age or older in cancer clinical trials.

21 January 2018

1 reference

Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials

21 January 2018

1 reference

Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review

21 January 2018

1 reference

The burden of community-acquired pneumonia in seniors: results of a population-based study

21 January 2018

1 reference

Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy

21 January 2018

1 reference

Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin

21 January 2018

1 reference

Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia

21 January 2018

1 reference

Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study

21 January 2018

1 reference

Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience

21 January 2018

1 reference

Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults

21 January 2018

1 reference

Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults

21 January 2018

1 reference

Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies

21 January 2018

1 reference

Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia

21 January 2018

1 reference

A randomized study of sequential intravenous/oral moxifloxacin in comparison to sequential intravenous ceftriaxone/oral cefuroxime axetil in patients with hospital-acquired pneumonia

21 January 2018

1 reference

Tazobactam/piperacillin for moderate-to-severe pneumonia in patients with risk for aspiration: comparison with imipenem/cilastatin

21 January 2018

1 reference

Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia.

21 January 2018

1 reference

Reappraisal of clindamycin IV monotherapy for treatment of mild-to-moderate aspiration pneumonia in elderly patients

21 January 2018

1 reference

A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia

21 January 2018

1 reference

Clinical efficacy and safety of a short regimen of azithromycin sequential therapy vs standard cefuroxime sequential therapy in the treatment of community-acquired pneumonia: an international, randomized, open-label study

21 January 2018

1 reference

Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors

21 January 2018

1 reference

Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia

21 January 2018

1 reference

A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation

21 January 2018

1 reference

Moxifloxacin vs ampicillin/sulbactam in aspiration pneumonia and primary lung abscess

21 January 2018

1 reference

Once-daily cefepime versus ceftriaxone for nursing home-acquired pneumonia.

21 January 2018

1 reference

Efficacy and safety of azithromycin 1 g once daily for 3 days in the treatment of community-acquired pneumonia: an open-label randomised comparison with amoxicillin-clavulanate 875/125 mg twice daily for 7 days.

21 January 2018

1 reference

Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia

21 January 2018

1 reference

Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors

21 January 2018

1 reference

A clinical comparative study of piperacillin and sulbactam/ampicillin in patients with community-acquired bacterial pneumonia

21 January 2018

1 reference

Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia

21 January 2018

1 reference

Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.

21 January 2018

1 reference

Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia

21 January 2018

1 reference

Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy

21 January 2018

1 reference

Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

Ertapenem versus cefepime for initial empirical treatment of pneumonia acquired in skilled-care facilities or in hospitals outside the intensive care unit

21 January 2018

1 reference

Clinical comparative study of sulbactam/ampicillin and imipenem/cilastatin in elderly patients with community-acquired pneumonia

21 January 2018

1 reference

Long-term consequences of severe infections

21 January 2018

1 reference

Pneumonia: still the old man's friend?

21 January 2018

1 reference

Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure

21 January 2018

1 reference

Patients included in randomised controlled trials do not represent those seen in clinical practice: focus on antimicrobial agents

21 January 2018

1 reference

How to get older people included in clinical studies

21 January 2018

1 reference

Harnessing technology to improve clinical trials: study of real-time informatics to collect data, toxicities, image response assessments, and patient-reported outcomes in a phase II clinical trial.

21 January 2018

1 reference

Ethics and regulatory complexities for pragmatic clinical trials.

21 January 2018

1 reference

Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance

21 January 2018

1 reference

Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/JGS.13250

1 reference

2 September 2017

1 reference